BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31378916)

  • 1. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
    Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
    Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
    Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
    Yang IA; Fong KM; Sim EH; Black PN; Lasserson TJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD002991. PubMed ID: 17443520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
    Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
    COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
    Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E
    Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
    N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
    Woods JA; Usery JB; Self TH; Finch CK
    South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
    Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
    Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
    Magnussen H; Watz H; Kirsten A; Decramer M; Dahl R; Calverley PM; Towse L; Finnigan H; Tetzlaff K; Disse B
    Respir Med; 2014 Apr; 108(4):593-9. PubMed ID: 24477080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program.
    Albers M; Schermer T; van den Boom G; Akkermans R; van Schayck C; van Herwaarden C; van Weel C
    Chest; 2004 Dec; 126(6):1815-24. PubMed ID: 15596679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.